

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Host blood transcriptomic biomarkers of tuberculosis disease in people living with HIV: a systematic review protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-048623
Article Type:	Protocol
Date Submitted by the Author:	02-Jan-2021
Complete List of Authors:	<p>Mendelsohn, Simon; University of Cape Town Faculty of Health Sciences, South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology</p> <p>Mulenga, Humphrey; University of Cape Town Faculty of Health Sciences, South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology</p> <p>Mbandi, Stanley; University of Cape Town Faculty of Health Sciences, South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology</p> <p>Darboe, Fatoumatta; University of Cape Town Faculty of Health Sciences, South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology</p> <p>Shelton, Mary; University of Cape Town, Bongani Mayosi Health Sciences Library</p> <p>Scriba, Thomas; University of Cape Town Faculty of Health Sciences, South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology</p> <p>Hatherill, Mark; University of Cape Town Faculty of Health Sciences, South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology</p>
Keywords:	Tuberculosis < INFECTIOUS DISEASES, HIV & AIDS < INFECTIOUS DISEASES, Molecular diagnostics < INFECTIOUS DISEASES

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Host blood transcriptomic biomarkers of tuberculosis disease in people living with HIV: a systematic review protocol

Simon C Mendelsohn¹, Humphrey Mulenga¹, Stanley Kimbung Mbandi¹, Fatoumatta Darboe¹, Mary Shelton², Thomas J Scriba^{1*}, Mark Hatherill^{1*}

*TJS and MH contributed equally to this work.

Author affiliations:

¹South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.

²Bongani Mayosi Health Sciences Library, University of Cape Town, Cape Town, South Africa.

Corresponding author: Mark Hatherill

Email: Mark.Hatherill@uct.ac.za **Telephone:** +27 (0) 21 406 6080

Postal address: South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Anzio Road, Observatory, 7935, Cape Town, South Africa.

Keywords: Human, host, blood, diagnostic, prognostic, predictive, transcriptomic, mRNA, gene expression, biomarker, signature, tuberculosis, *Mycobacterium*, TB, HIV

Word count: 2,670

1
2 25
3
4 26
5 27
6
7 28
8 29
9
10 30
11 31
12
13 32
14
15 33
16 34
17
18 35
19 36
20
21 37
22 38
23
24 39
25 40
26 41
27 42
28 43
29 44
30 45
31 46
32 47
33 48
34 49
35 50
36 51
37 52
38 53
39 54
40 55
41 56
42 57
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction

Current tuberculosis triage and predictive tools offer poor accuracy and are ineffective for detecting asymptomatic disease in people living with HIV (PLHIV). Host tuberculosis transcriptomic biomarkers hold promise for diagnosing prevalent and predicting progression to incident tuberculosis, and guiding further investigation, preventive therapy, and follow-up. We aim to conduct a systematic review of performance of transcriptomic signatures of tuberculosis in PLHIV.

Methods and analysis

We will search *MEDLINE (PubMed)*, *WOS Core Collection*, *Biological Abstracts*, and *SciELO Citation Index (Web of Science)*, *Africa-Wide Information and General Science Abstracts (EBSCOhost)*, *Scopus*, and *Cochrane Central Register of Controlled Trials* databases for articles published in English between 1990–2020. Case-control, cross-sectional, cohort and randomised-controlled studies evaluating performance of diagnostic and prognostic host-response transcriptomic signatures in PLHIV of all ages and settings will be included. Eligible studies will include PLHIV in signature test or validation cohorts, and use microbiological, clinical, or composite reference standards for pulmonary or extra-pulmonary tuberculosis diagnosis. Study quality will be evaluated using the “Quality Assessment of Diagnostic Accuracy Studies-2” tool and cumulative review evidence assessed using the “Grading of Recommendations Assessment, Development and Evaluation” approach. Study selection, quality appraisal, and data extraction will be performed independently by two reviewers. Study, cohort, and signature characteristics of included studies will be tabulated, and a narrative synthesis of findings presented. Primary outcomes of interest, biomarker sensitivity and specificity with estimate precision, will be summarised in forest plots. Expected heterogeneity in signature characteristics, study settings, and study designs precludes meta-analysis and pooling of results. Review reporting will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy Studies guidelines.

Ethics and dissemination

Formal ethics approval is not required as primary human participant data will not be collected. Results will be disseminated through peer-reviewed publication and conference presentation.

PROSPERO registration: CRD42021224155

Strengths and limitations of this study

- This systematic review will be the first to synthesise the published literature on host-response blood transcriptomic biomarkers for diagnosing prevalent and predicting progression to incident tuberculosis disease in people living with HIV.
- Data reporting will adhere to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) guidelines.
- Strengths of this protocol include a clear research question with explicit and reproducible methodology, comprehensive eligibility criteria with a stringent microbiological reference standard as well as clinical and composite reference standards for tuberculosis disease, inclusion of participants of all ages and recruitment settings, a rigorous and inclusive search strategy of multiple databases, and structured evaluation of study bias and evidence quality using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) assessment tool and Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
- Inclusion will be restricted to published studies in English which may introduce publication and language bias.
- Anticipated limitations of this review include heterogenous signature, study, and cohort designs, precluding meta-analysis.

1 2 76 INTRODUCTION

3 77 In 2019 44% of the estimated 815,000 global incident tuberculosis cases amongst people living with
4 78 HIV (PLHIV) went unreported or undiagnosed, with an estimated case fatality rate of 26% amongst
5 79 all PLHIV.¹ We currently rely on symptom screening, which performs poorly as a triage test in PLHIV,
6 80 to find these missing cases.² A test which could detect *Mycobacterium tuberculosis* (*Mtb*) infected
7 81 individuals at highest risk of progression to disease, so-called incipient tuberculosis, or
8 82 asymptomatic, minimal, or sub-clinical tuberculosis disease prior to symptom onset, facilitating
9 83 earlier treatment and *Mtb* clearance, may reduce morbidity and mortality in PLHIV, and help to
10 84 interrupt transmission. Tuberculin skin testing (TST) and the interferon gamma release assay
11 85 (IGRA), which reflect a memory T-cell response following *Mtb* sensitisation, are unable to distinguish
12 86 current versus cleared *Mtb* infection and are thus not sufficiently specific for predicting progression
13 87 to tuberculosis disease.^{3,4} In tuberculosis-endemic settings, very high rates of *Mtb* exposure and
14 88 consequent TST or IGRA positivity limit the utility of these tests to guide administration of
15 89 tuberculosis preventive therapy (TPT). IGRA also has lower sensitivity and produces more
16 90 indeterminate results amongst PLHIV than amongst those without HIV.⁵ There is therefore a need
17 91 for more specific, rapid, non-sputum tuberculosis triage and prognostic tools to direct further
18 92 diagnostic testing and TPT in PLHIV.

19 93
20 94 Host-response blood transcriptomic biomarkers show potential for diagnosing^{6,7} prevalent
21 95 tuberculosis and predicting⁸ progression from asymptomatic quiescent or incipient infection to active
22 96 disease. A recent systematic review⁹ found 20 studies evaluating 25 predominantly interferon-
23 97 stimulated gene (ISG) transcriptomic signatures of tuberculosis in adults without HIV; 17 signatures
24 98 met at least one of the World Health Organization (WHO) Target Product Profile (TPP) minimum
25 99 performance criterion for a tuberculosis triage test (sensitivity 90%; specificity 70%)¹⁰ and one
26 100 signature¹¹ predicted progression to tuberculosis disease through 6 months with performance
27 101 meeting the minimum WHO TPP criteria for a test predicting progression to active disease (sensitivity
28 102 and specificity 75%)¹². Although these results bode well for translation to a point-of-care
29 103 transcriptomic triage test for people without HIV, there is evidence that HIV infection may affect
30 104 signature score through induction of ISGs¹³. An unsuppressed HIV viral load may thus erode
31 105 diagnostic accuracy of ISG-dominant transcriptomic biomarkers. There are currently no systematic
32 106 reviews evaluating diagnostic and prognostic performance of host-response blood transcriptomic
33 107 tuberculosis biomarkers in PLHIV. Biomarkers selected for further development as point-of-care
34 108 tests and field implementation studies in high-tuberculosis-risk groups should ideally perform well in
35 109 people without HIV and in PLHIV, before and during antiretroviral therapy (ART).

36 110
37 111 We aim to systematically review the published literature on host-response blood transcriptomic
38 112 biomarkers for diagnosing prevalent and predicting progression to incident tuberculosis disease in
39 113 PLHIV. Our objectives are to provide an evidence synthesis of existing transcriptomic host-response

1
2 114 biomarkers of tuberculosis disease evaluated in PLHIV; to appraise the quality of evidence, describe
3 115 study design and biomarker characteristics, and compare the diagnostic and prognostic performance
4 116 of the biomarkers with the WHO TPP criteria.
5 117

8 118 **RESEARCH QUESTION**

9
10 119 How do host blood transcriptomic signatures of tuberculosis perform in diagnosing prevalent and
11 120 predicting progression to incident tuberculosis disease in PLHIV compared to the WHO TPP criteria?
12 121

13 122 **Population:** PLHIV of all ages and from all settings

14 123 **Index test:** Blood transcriptomic biomarkers

15 124 **Reference standard:** Microbiologically-confirmed tuberculosis (primary endpoint) or non-
16 125 microbiologically-confirmed, presumptive clinical tuberculosis (secondary endpoint)
17 126

18 127 **Comparator:** WHO TPP criteria

19 128 **Outcome:** Diagnosis of prevalent and prediction of progression to incident tuberculosis disease
20 129

21 130 **METHODS AND ANALYSIS**

22 131 This protocol was developed in line with the Preferred Reporting Items for Systematic review and
23 132 Meta-Analysis Protocols (PRISMA-P)^{14,15} guidelines (Supplementary File). The systematic review
24 133 will adhere to the Preferred Reporting Items for Systematic reviews and Meta-Analysis of Diagnostic
25 134 Test Accuracy Studies (PRISMA-DTA)¹⁶ recommendations. Significant amendments made to the
26 135 protocol will be documented and published alongside the results of the systematic review. This
27 136 systematic review protocol was registered with the International Prospective Register of Systematic
28 137 Reviews (PROSPERO) on 02 January 2021 with registration number CRD42021224155.
29 138

30 139 **Definitions and study eligibility criteria**

31 140 *Study design*

32 141 Study eligibility criteria are summarised in **Table 1**. We will consider cross-sectional and case-control
33 142 studies, prospective and retrospective cohort studies, and randomised control trials of human host
34 143 diagnostic or prognostic transcriptomic signatures of tuberculosis that report test or validation cohort
35 144 performance data. Studies that only report signature discovery cohort performance, or treatment
36 145 response and failure monitoring cohorts, will not be considered.
37 146

38 147 *Study participants and setting*

39 148 We will consider study participants living with HIV of all ages, ethnicities, and settings, and include
40 149 ART-naïve and ART-experienced individuals. Eligible studies must include participants living with
41 150 HIV in either the signature test or validation cohorts.
42 151

1

2 152 *Index test*

3

4 153 We define diagnostic blood transcriptomic signatures of tuberculosis as host whole-blood or
5 154 peripheral blood mononuclear cell (PBMC) biomarkers consisting of one or more host transcripts
6 155 which are able to diagnose or predict progression to tuberculosis disease and have been validated
7 156 in external cohorts. Studies which only evaluate non-host (mycobacterial) transcriptional profiles as
8 157 diagnostic biomarkers will be excluded.

11 158

13 159 *Tuberculosis endpoints*

14 160 The primary tuberculosis disease endpoint is defined by a positive microbiological test from sputum
15 161 or other bodily fluids, such as solid and liquid mycobacterial culture, Xpert MTB/RIF assay, or smear
16 162 for acid-fast bacilli (auramine and Ziehl-Neelsen stains). Microbiologically-confirmed extra-
17 163 pulmonary tuberculosis disease (such as disseminated tuberculosis and tuberculosis meningitis) will
18 164 also be included. The secondary tuberculosis disease endpoint is defined by non-microbiologically-
19 165 confirmed, presumptive clinical tuberculosis diagnoses through techniques such as chest
20 166 radiography, ultrasonography, fluid aspirate (e.g. lymph node and cerebrospinal fluid aspirates)
21 167 chemistry, symptomatology, and composite non-microbiological endpoints. Latent tuberculosis
22 168 infection is defined by a positive tuberculin skin test (TST) or interferon-gamma release assay
23 169 (IGRA).

30 170

31 171 Eligible studies will use the primary microbiological tuberculosis reference standard endpoint or
32 172 secondary presumptive clinical diagnosis endpoint for tuberculosis disease cases. Studies which do
33 173 not separate clinically- from microbiologically-diagnosed cases will be excluded. Studies which use
34 174 smear microscopy as a reference standard will be reported in separate figures due to reduced
35 175 diagnostic certainty. Eligible studies must include healthy individuals, individuals with latent *Mtb*
36 176 infection, or individuals with other diseases as a control group. Tuberculosis disease diagnosed
37 177 within one month of conducting the index test is presumed to be prevalent disease (diagnostic
38 178 studies); incident tuberculosis is defined as tuberculosis disease diagnosed more than one month
39 179 following study enrolment or measurement of index test. Prognostic studies are defined as
40 180 prospective studies in which participants are followed up for progression to incident tuberculosis
41 181 disease with prospective or retrospective measurement of a transcriptomic biomarker from blood
42 182 RNA samples collected at enrolment.

51 183

52 184 *Outcome measures*

53 185 Outcome measures of interest will include reported host tuberculosis transcriptomic signature
54 186 sensitivity and specificity in test or validation cohorts, or reported data which enable the
55 187 reconstruction of a two-by-two table for test accuracy calculation for PLHIV. Studies which do not
56 188 report any measures of signature performance, do not clearly state the case definition of tuberculosis
57 189 disease, do not report primary data, lack explicit description of methodology, or do not separately

report signature performance in PLHIV, will be excluded. If data supplied in the papers are not sufficient to reconstruct two-by-two tables, we will contact the corresponding authors to request additional data. Corresponding authors will be given up to four weeks to respond to email requests.

Table 1: Study eligibility criteria

Study inclusion criteria
1. Study design: Cross-sectional, case-control, prospective/retrospective cohort, or randomised control
2. Study reports test and/or validation cohort diagnostic or prognostic performance data
3. Study participants include people living with HIV in test and/or validation cohort. Studies including human participants of all ages, geographic locations, and settings will be considered.
4. Index test: Study evaluates whole-blood or peripheral blood mononuclear cell (PBMC) diagnostic transcriptomic signatures of tuberculosis consisting of one or more host transcripts
5. Control group: Includes healthy individuals, individuals with <i>Mtb</i> infection, and/or individuals with other diseases.
6. Tuberculosis endpoint: Studies will provide clearly defined microbiological tuberculosis reference standard or presumptive clinical diagnosis definitions (<i>see Tuberculosis endpoints</i>)
7. Outcome measures: Host tuberculosis transcriptomic signature sensitivity and specificity in test or validation cohorts, or reported data which enable the reconstruction of a two-by-two table for test accuracy calculation
Study exclusion criteria
1. Study design: Statistical or mathematical modelling articles, cost-effectiveness studies, opinion pieces, narrative reviews, case studies, case series, and letters to editors which do not include original data will not be considered.
2. Study only reports signature discovery cohort performance, or treatment response, or failure monitoring cohorts
3. Study participants do not include PLHIV, or it is not possible to stratify results by HIV status
4. Index test: Study evaluates non-host (mycobacterial) transcriptional profiles only
5. Control group: Studies which do not report a definition of the control group, or do not stratify results by control group definition
6. Tuberculosis endpoint: Studies which do not clearly state the case definition of tuberculosis disease, or do not separate clinically- from microbiologically-diagnosed cases
7. Outcome measures: Studies which do not report any measures of signature performance, or do not separately report signature performance in PLHIV
8. Article not available in English
9. Full-text article not available
10. Study published before 1 January 1990 or after 31 December 2020
11. Studies conducted in animals

Search strategy

We will systematically search for published full-text articles using Medical Subject Headings (MeSH) and keyword search terms as outlined for our PubMed (*MEDLINE*) search in **Table 2**. Our systematic literature search will be adapted to *WOS Core Collection*, *Biological Abstracts*, and *SciELO Citation Index (via Web of Science)*, *Africa-Wide Information* and *General Science Abstracts (via EBSCOhost)*, *Scopus*, and *Cochrane Central Register of Controlled Trials* databases. We will review reference lists of eligible articles and perform forward citation tracking using a citation index (such as *Scopus* or *Science Citation Index via Web of Science*) to identify further articles and reports missed by the electronic database search.¹⁷ Only full-text articles will be considered. Statistical or mathematical modelling articles, cost-effectiveness studies, opinion pieces, narrative reviews, case

1
2 206 studies, case series, and letters to editors which do not include original data will not be considered.
3
4 207 We will consider articles published in English between 1 January 1990 and 31 December 2020.

5 208

6
7 209 **Table 2:** PubMed Search strategy, modified as needed for other electronic databases

Diagnostic search terms:		
#1	MeSH terms:	Diagnosis [MeSH] Diagnosis [subheading]
#2	Text word:	diagnose OR diagnostic OR diagnosis OR detect OR detection OR predict OR prediction OR predictive OR prognose OR prognostic OR prognosis OR receiver operating characteristic OR receiver operator characteristic OR ROC OR risk OR screening OR sensitivity OR specificity OR area under the curve OR AUC OR accuracy
#3	#1 OR #2	
Transcriptomic:		
#4	MeSH terms:	RNA, Messenger [MeSH]
#5	Text word:	gene OR genes OR mRNA OR messenger ribonucleic acid OR messenger RNA OR transcription OR transcriptome OR transcriptional OR transcriptomic
#6	#4 OR #5	
Biomarker:		
#7	MeSH terms:	Biomarkers/blood [MeSH]
#8	Text word:	assay OR assays OR biomarker OR biomarkers OR bio-signature OR bio-signatures OR expression OR marker OR markers OR profile OR profiling OR profiles OR signature OR signatures OR surrogate endpoint OR test OR tests OR tool OR tools
#9	#7 OR #8	
Tuberculosis:		
#10	MeSH terms:	Tuberculosis [MeSH] Mycobacterium, Tuberculosis [MeSH]
#11	Text word:	tuberculosis OR TB OR MTB
#12	#10 OR #11	
HIV:		
#13	MeSH terms:	HIV[MeSH] Acquired Immunodeficiency Syndrome [MeSH]
#14	Text word:	HIV OR Human Immunodeficiency Virus OR AIDS virus OR Acquired Immune Deficiency Syndrome Virus
#15	#13 OR #14	
#16	#3 AND #6 AND #9 AND #12 AND #15	
#17	Filter 1990-2020	
#18	Filter to English only	

49 210

50 51 211 **Data management**

52 212 EndNote bibliographic software will be used to manage, and screen references and full-text articles
53
54 213 as previously described¹⁸. Two reviewers will independently conduct the literature search and screen
55
56 214 the search outputs for potential inclusion. After removal of duplicates, the selection process will
57 215 include an initial screening of article titles and abstracts (include, exclude, or unsure), followed by
58
59 216 full text review for eligibility. Only studies meeting the eligibility criteria will be included in the
60 217 systematic review. The two reviewers will compare their results and resolve any disagreements or

uncertainties by discussion. If consensus cannot be reached, the discrepancies will be referred to a third a reviewer for adjudication. Study selection will be summarised in a PRISMA flow diagram.

Data extraction

Data elements (**Table 3**) of included studies will be independently extracted and coded by the two reviewers using an electronic data collection form and results will be collated. The data extraction form will be piloted on the first five studies selected for inclusion to assess agreement between the two reviewers and need for amendments to the data collection form.

Table 3: Summary of data extraction

Study identification	Study first author; article title; journal title; publication year; study type (discovery and/or validation; diagnostic and/or prognostic);
Cohort identification and methodology	Cohort first author; journal title; publication year; GEO database; country or geographic region of the study; cohort type (discovery, test, or validation); study design (cross-sectional, case control, prospective cohort, randomised control trial, or other); study setting; age groups of participants (child, adolescent, adult, or mixed); sample size; sampling method and participant selection (consecutive, convenience, random, other); sample representative of target population (were participants with suspected but unconfirmed tuberculosis excluded introducing spectrum bias); control group definition (LTBI, healthy control, or other disease); microbiological reference standard(s) used to diagnose tuberculosis disease; clinical and/or composite non-microbiological methods of tuberculosis diagnosis; method of LTBI diagnosis (TST >5mm, TST >10mm, IGRA: T-Spot.TB or QuantiFERON); duration of follow-up for prediction of progression to incident tuberculosis; signature measurement method (RNA sequencing, microarray, PCR, or other) and sample type (whole blood or PBMC); flow and timing of index and reference test measurement; study blinding
Signature characteristics	Signature discovery author; publication year; country or geographic region of discovery cohort; study design; signature discovery method (RNA sequencing, microarray, PCR, or other) and sample type (whole blood or PBMC); transcripts included in the signature; signature model; intended use of signature
Outcome data	True and false positives; true and false negatives; sensitivity; specificity; area under the curve; signature positivity rate (prevalence) in study population; signature cut-off/threshold applied (if reported); 95% confidence intervals for all estimates

GEO, gene expression omnibus. LTBI, latent tuberculosis infection. TST, tuberculin skin test. IGRA, interferon-gamma release assay. RNA, ribonucleic acid. PCR, polymerase chain reaction. PBMC, peripheral blood mononuclear cells.

A study may evaluate multiple signatures using several validation cohorts. Studies and cohorts will be designated by the first author name and year of publication (e.g. Author2019a) and signatures by first author and number of transcripts (e.g. Author11).

1 2 236 **Quality appraisal**

3 237 The methodological quality of included studies will be assessed using the Quality Assessment of
4
5 238 Diagnostic Accuracy Studies-2 (QUADAS-2) assessment tool¹⁹, a widely used tool for classification
6
7 239 of the quality of the evidence from diagnostic accuracy studies. Risk of bias and applicability
8 240 concerns for individual study patient selection, index test, reference standard, and study flow and
9
10 241 timing will be reported as low risk, high risk, or unclear risk.

11 242
12
13 243 Two independent reviewers will assess the methodological quality of eligible trials and score the
14
15 244 selected studies. Disagreements will be resolved through discussion and/or a third reviewer. The
16 245 risk of bias for each outcome across individual studies will be summarised in a risk of bias table. A
17
18 246 review-level narrative summary of the risk of bias will also be provided.

19 247
20
21 248 We will assess the cumulative quality of evidence synthesised by the systematic review using the
22
23 249 “Grading of Recommendations Assessment, Development and Evaluation” (GRADE) approach²⁰
24 250 with classification based on study design and limitations, indirectness, inconsistency, imprecision,
25
26 251 and publication bias.²¹

27 252 28 29 253 **Data analysis and reporting**

30 254 Narrative synthesis of the findings from the eligible studies, including study design and signature
31
32 255 characteristics, discovery and validation population characteristics, and performance of each
33
34 256 signature, stratified by diagnostic (prevalent tuberculosis) and prognostic (incident tuberculosis)
35 257 tests, study design, site of disease (pulmonary or extra-pulmonary), microbiological or composite
36
37 258 clinical reference standards, and control group (healthy, latent-*Mtb* infected, or other disease) will be
38 259 provided. We anticipate considerable clinical and methodological heterogeneity between studies,
39
40 260 with each study evaluating different transcriptomic signatures for the diagnosis of tuberculosis
41
42 261 disease. In addition, signature score cut-off values will not be standardised for calculating signature
43 262 sensitivity and specificity. As such, we do not plan to perform a meta-analysis. If sufficient data is
44
45 263 available, subgroup analysis by CD4 cell count, HIV plasma viral load, TPT and ART status may be
46 264 undertaken. Signature sensitivity and specificity will be summarised using forest plots.

47 265 48 49 266 **PATIENT AND PUBLIC INVOLVEMENT**

50
51 267 As this research will be based on previously published data, there will be no patient and public
52
53 268 involvement in the design, interpretation or dissemination of the findings.

54 269 55 56 270 **ETHICS AND DISSEMINATION**

57 271 This systematic review protocol does not require formal ethics approval as primary human participant
58
59 272 data will not be collected. The results will be disseminated through a peer-reviewed publication and
60 273 conference presentation.

DISCUSSION

Transcriptomic biomarkers hold promise as markers of incipient, asymptomatic, minimal, or sub-clinical tuberculosis for targeted screening of high risk populations, guiding targeted TPT and intensified follow-up.²² There is also need for non-sputum-based triage tests for detection of sub-clinical and clinical tuberculosis, to trigger further intensified investigation and therapeutic intervention.²³

While several studies have recently systematically evaluated transcriptomic biomarker performance for incipient and prevalent tuberculosis,^{7-9,24,25} none have specifically focussed on PLHIV. As highlighted in the introduction, PLHIV are over-represented in global tuberculosis incidence and have a particularly high case-fatality rate. PLHIV are also less likely to expectorate sputum while paucibacillary tuberculosis is more common, factors that make diagnosis even more challenging in PLHIV.²⁶ As such, it is important that non-sputum tuberculosis biomarkers selected for further development and commercialisation are efficacious in this high-risk population. This systematic review will be the first to provide synthesis of transcriptomic signature performance in diagnosing prevalent and predicting progression to incident tuberculosis in PLHIV.

A rigorous protocol acts as a roadmap to the reviewers; by pre-specifying and registering a detailed systematic review protocol, we aim to reduce bias in selection of studies and reporting of results, reducing arbitrary decision-making in data extraction, quality assessment, and analysis. This protocol will allow journal editors, peer reviewers, and readers to critically gauge the review completeness and transparency, identify deviations from planned methods, and identify biased interpretation of review results and conclusions, holding accountability to the reviewers.¹⁴ Specific strengths of this systematic review protocol include a clear research question, explicit and reproducible methodology, comprehensive eligibility criteria with a stringent microbiological reference standard, as well as clinical and composite endpoints for tuberculosis disease, inclusion of participants of all ages and recruitment settings, a rigorous and inclusive search strategy of multiple databases, and structured evaluation of study bias and evidence quality.

Potential limitations of this study include the heterogeneity of measures and outcomes reported by biomarker discovery and validation studies, with few studies applying a-priori biomarker thresholds across cohorts or one that is relevant to the WHO TPP criteria. We anticipate scant reporting of signature performance stratified by ART and TPT status, CD4 cell count, and HIV viral load, limiting sub-group analysis. We are also aware that much of the tuberculosis biomarker literature in PLHIV emanates from Sub-Saharan Africa, potentially limiting generalisability of findings. We expect significant heterogeneity in signature, study, and cohort designs, precluding meta-analysis. Inclusion of studies published in English only may introduce publication bias. Diagnosing tuberculosis in

1
2 312 PLHIV can be particularly challenging due to more common paucibacillary disease and difficulties in
3 313 expectorating sputum in advanced HIV; we thus chose to include clinical and composite diagnostic
4 314 endpoints which are still used in many settings to presumptively initiate tuberculosis treatment.
5 315 However, this may lead to overdiagnosis of tuberculosis and under-estimation of transcriptomic
6 316 biomarker performance. Clinically diagnosed symptomatic disease without microbiological
7 317 confirmation remains an enigma which merits further attention beyond the scope of this review.

8 318
9
10 319 This review will inform further optimisation and development of transcriptomic signatures as they
11 320 progress through the clinical implementation pipeline. Transcriptomic signatures discovered and
12 321 validated in high quality studies with well-designed cohorts and meeting or approaching the WHO
13 322 TPP criteria may be considered for advancement for further prospective validation in real-world
14 323 health-care settings and development as point-of-care tests for PLHIV who are at elevated risk of
15 324 tuberculosis and its sequelae. The review may also inform whether current WHO TPP benchmarks
16 325 can realistically be attained in PLHIV, and whether they need to be revisited.

17 326 18 327 **AUTHORS' CONTRIBUTIONS**

19 328 SCM and MH conceived the idea and planned the study protocol. SCM, MS, and MH undertook a
20 329 scoping search and designed the search strategy. SCM wrote the protocol under supervision from
21 330 MH and TJS. SCM, HM, SKM, FD, MS, TJS, and MH have contributed to, reviewed, and approved
22 331 the final protocol, and will participate in the interpretation of the results.

23 332 24 333 **FUNDING STATEMENT**

25 334 This research received no specific grant from any funding agency in the public, commercial, or not-
26 335 for-profit sectors. SCM is a recipient of PhD funding from the Fogarty International Center of the
27 336 National Institutes of Health (NIH) under Award Number D43 TW010559, the Harry Crossley Clinical
28 337 Research Fellowship, the South African Medical Research Council (SAMRC) through its Division of
29 338 Research Capacity Development under the SAMRC Clinician Researcher Programme, and the
30 339 South African Medical Association (SAMA). The content is solely the responsibility of the authors
31 340 and does not necessarily represent the official views of the NIH, Harry Crossley Foundation,
32 341 SAMRC, or SAMA.

33 342 34 343 **COMPETING INTERESTS STATEMENT**

35 344 TJS is a co-inventor of two patents of host-blood transcriptomic signatures of tuberculosis risk.

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 345 **REFERENCES**

- 3 346 1. WHO. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
4 347 https://www.who.int/tb/publications/global_report/en/ (accessed October 15, 2020).
- 5 348 2. Hamada Y, Lujan J, Schenkel K, Ford N, Getahun H. Sensitivity and specificity of WHO's
6 349 recommended four-symptom screening rule for tuberculosis in people living with HIV: a
7 350 systematic review and meta-analysis. *Lancet HIV*. 2018;5(9):e515-e23. doi: 10.1016/S2352-
8 351 3018(18)30137-1.
- 9 352 3. Barry CE, 3rd, Boshoff HI, Dartois V, Dick T, Ehrh S, Flynn J, et al. The spectrum of latent
10 353 tuberculosis: rethinking the biology and intervention strategies. *Nature Reviews Microbiology*.
11 354 2009;7(12):845-55. doi: 10.1038/nrmicro2236.
- 12 355 4. Mahomed H, Hawkridge T, Verver S, Abrahams D, Geiter L, Hatherill M, et al. The tuberculin
13 356 skin test versus QuantiFERON TB Gold(R) in predicting tuberculosis disease in an
14 357 adolescent cohort study in South Africa. *PLoS ONE*. 2011;6(3):e17984. doi:
15 358 10.1371/journal.pone.0017984.
- 16 359 5. Metcalfe JZ, Everett CK, Steingart KR, Cattamanchi A, Huang L, Hopewell PC, et al.
17 360 Interferon-gamma release assays for active pulmonary tuberculosis diagnosis in adults in
18 361 low- and middle-income countries: systematic review and meta-analysis. *Journal of
19 362 Infectious Diseases*. 2011;204 Suppl 4:S1120-9. doi: 10.1093/infdis/jir410.
- 20 363 6. Warsinske H, Vashisht R, Khatri P. Host-response-based gene signatures for tuberculosis
21 364 diagnosis: A systematic comparison of 16 signatures. *PLoS Medicine*. 2019;16(4):e1002786.
22 365 doi: 10.1371/journal.pmed.1002786.
- 23 366 7. Turner CT, Gupta RK, Tsaliki E, Roe JK, Mondal P, Nyawo GR, et al. Blood transcriptional
24 367 biomarkers for active pulmonary tuberculosis in a high-burden setting: a prospective,
25 368 observational, diagnostic accuracy study. *Lancet Respir Med*. 2020;8(4):407-19. doi:
26 369 10.1016/S2213-2600(19)30469-2.
- 27 370 8. Gupta RK, Turner CT, Venturini C, Esmail H, Rangaka MX, Copas A, et al. Concise whole
28 371 blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-
29 372 level pooled meta-analysis. *Lancet Respir Med*. 2020;8(4):395-406. doi: 10.1016/S2213-
30 373 2600(19)30282-6.
- 31 374 9. Mulenga H, Zauchenberger CZ, Bunyasi EW, Mbandi SK, Mendelsohn SC, Kagina B, et al.
32 375 Performance of diagnostic and predictive host blood transcriptomic signatures for
33 376 Tuberculosis disease: A systematic review and meta-analysis. *PLoS ONE*.
34 377 2020;15(8):e0237574. doi: 10.1371/journal.pone.0237574.
- 35 378 10. WHO. High-priority target product profiles for new tuberculosis diagnostics: report of a
36 379 consensus meeting. Geneva: World Health Organization, 2014.
37 380 www.who.int/tb/publications/tpp_report/en/ (accessed May 22, 2020).
- 38 381 11. Warsinske HC, Rao AM, Moreira FMF, Santos PCP, Liu AB, Scott M, et al. Assessment of
39 382 Validity of a Blood-Based 3-Gene Signature Score for Progression and Diagnosis of
40 383 Tuberculosis, Disease Severity, and Treatment Response. *JAMA Netw Open*.
41 384 2018;1(6):e183779. doi: 10.1001/jamanetworkopen.2018.3779.
- 42 385 12. WHO. Consensus Meeting Report: Development of a Target Product Profile (TPP) and a
43 386 framework for evaluation for a test for predicting progression from tuberculosis infection to
44 387 active disease. Geneva: World Health Organization, 2017.
45 388 <http://apps.who.int/iris/handle/10665/259176> (accessed May 22, 2020).
- 46 389 13. Darboe F, Mbandi SK, Naidoo K, Yende-Zuma N, Lewis L, Thompson EG, et al. Detection
47 390 of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic
48 391 Risk Signature in HIV-Infected Persons on Antiretroviral Therapy. *Front Microbiol*.
49 392 2019;10:1441. doi: 10.3389/fmicb.2019.01441.
- 50 393 14. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting
51 394 items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst
52 395 Rev*. 2015;4:1. doi: 10.1186/2046-4053-4-1.
- 53 396 15. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting
54 397 items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and
55 398 explanation. *BMJ*. 2015;350:g7647. doi: 10.1136/bmj.g7647.
- 56 399 16. McInnes MDF, Moher D, Thoms BD, McGrath TA, Bossuyt PM, the P-DTAG, et al. Preferred
57 400 Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy

- 1
2 401 Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-96. doi:
3 402 10.1001/jama.2017.19163.
4 403 17. Greenhalgh T, Peacock R. Effectiveness and efficiency of search methods in systematic
5 404 reviews of complex evidence: audit of primary sources. BMJ. 2005;331(7524):1064-5. doi:
6 405 10.1136/bmj.38636.593461.68.
7 406 18. Peters MD. Managing and Coding References for Systematic Reviews and Scoping Reviews
8 407 in EndNote. Medical Reference Services Quarterly. 2017;36(1):19-31. doi:
9 408 10.1080/02763869.2017.1259891.
10 409 19. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2:
11 410 a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal
12 411 Medicine. 2011;155(8):529-36. doi: 10.7326/0003-4819-155-8-201110180-00009.
13 412 20. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an
14 413 emerging consensus on rating quality of evidence and strength of recommendations. BMJ.
15 414 2008;336(7650):924-6. doi: 10.1136/bmj.39489.470347.AD.
16 415 21. Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading
17 416 quality of evidence and strength of recommendations for diagnostic tests and strategies.
18 417 BMJ. 2008;336(7653):1106-10. doi: 10.1136/bmj.39500.677199.AE.
19 418 22. Scriba TJ, Mendelsohn SC. Headway made towards biosignatures for incipient tuberculosis.
20 419 Lancet Respir Med. 2020;8(4):328-30. doi: 10.1016/s2213-2600(19)30355-8.
21 420 23. Mendelsohn SC, Mbandi SK, Hatherill M, Scriba TJ. Blood transcriptional signatures for
22 421 tuberculosis testing. Lancet Respir Med. 2020;8(4):330-1. doi: 10.1016/S2213-
23 422 2600(20)30045-X.
24 423 24. Togun TO, MacLean E, Kampmann B, Pai M. Biomarkers for diagnosis of childhood
25 424 tuberculosis: A systematic review. PLoS ONE. 2018;13(9):e0204029. doi:
26 425 10.1371/journal.pone.0204029.
27 426 25. MacLean E, Broger T, Yerlikaya S, Fernandez-Carballo BL, Pai M, Denkinger CM. A
28 427 systematic review of biomarkers to detect active tuberculosis. Nat Microbiol. 2019;4(5):748-
29 428 58. doi: 10.1038/s41564-019-0380-2.
30 429 26. MacLean E, Saravu K, Pai M. Diagnosing active tuberculosis in people living with HIV: an
31 430 ongoing challenge. Current Opinion in HIV and AIDS. 2019;14(1):46-54. doi:
32 431 10.1097/COH.0000000000000512.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Host blood transcriptomic biomarkers of tuberculosis disease in people living with HIV: a systematic review protocol

Supplementary File: PRISMA-P 2015 Checklist

This checklist has been adapted for use with protocol submissions to *Systematic Reviews* from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews* 2015 4:1

Section/topic	#	Checklist item	Information reported		Location
			Yes	No	
ADMINISTRATIVE INFORMATION					
Title					
Identification	1a	Identify the report as a protocol of a systematic review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Line 2, Page 1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	<input type="checkbox"/>	<input type="checkbox"/>	N/A
Registration	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Line 57, Page 2; lines 135-136 page 5
Authors					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Page 1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 327-331, Page 12
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 133-134, Page 5
Support					
Sources	5a	Indicate sources of financial or other support for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 333-341, Page 12
Sponsor	5b	Provide name for the review funder and/or sponsor	<input type="checkbox"/>	<input type="checkbox"/>	N/A
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	<input type="checkbox"/>	<input type="checkbox"/>	N/A
INTRODUCTION					
Rationale	6	Describe the rationale for the review in the context of what is already known	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 96-111, Page 4
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 120-129, Page 5

Host blood transcriptomic biomarkers of tuberculosis disease in people living with HIV: a systematic review protocol

Supplementary File: PRISMA-P 2015 Checklist

Section/topic	#	Checklist item	Information reported		Location
			Yes	No	
METHODS					
Eligibility criteria	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Table 1; Lines 140-209, Pages 5-8
Information sources	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 192-209, Page 7-8
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Table 2, Page 8
STUDY RECORDS					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 213-221, Pages 8-9
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 213-221, Pages 8-9
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 223-236, Page 9
Data items	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Table 3, Page 9
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 186-194, Pages 6-7; Table 3, Page 9
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 238-248, Page 10

Host blood transcriptomic biomarkers of tuberculosis disease in people living with HIV: a systematic review protocol

Supplementary File: PRISMA-P 2015 Checklist

Section/topic	#	Checklist item	Information reported		Location
			Yes	No	
DATA					
Synthesis	15a	Describe criteria under which study data will be quantitatively synthesized	<input type="checkbox"/>	<input type="checkbox"/>	Lines 255-266, Page 10
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I^2 , Kendall's tau)	<input type="checkbox"/>	<input type="checkbox"/>	
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 264-266, Page 10
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 255-266, Page 10
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 306-319, Pages 11-12
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 250-253, Page 10

BMJ Open

Host blood transcriptomic biomarkers of tuberculosis disease in people living with HIV: a systematic review protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-048623.R1
Article Type:	Protocol
Date Submitted by the Author:	14-Jun-2021
Complete List of Authors:	<p>Mendelsohn, Simon; University of Cape Town Faculty of Health Sciences, South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology</p> <p>Mulenga, Humphrey; University of Cape Town Faculty of Health Sciences, South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology</p> <p>Mbandi, Stanley; University of Cape Town Faculty of Health Sciences, South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology</p> <p>Darboe, Fatoumatta; University of Cape Town Faculty of Health Sciences, South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology</p> <p>Shelton, Mary; University of Cape Town, Bongani Mayosi Health Sciences Library</p> <p>Scriba, Thomas; University of Cape Town Faculty of Health Sciences, South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology</p> <p>Hatherill, Mark; University of Cape Town Faculty of Health Sciences, South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology</p>
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	HIV/AIDS, Immunology (including allergy), Diagnostics, Global health, Respiratory medicine
Keywords:	Tuberculosis < INFECTIOUS DISEASES, HIV & AIDS < INFECTIOUS DISEASES, Molecular diagnostics < INFECTIOUS DISEASES

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2 1 **Host blood transcriptomic biomarkers of tuberculosis disease in people**
3
4 2 **living with HIV: a systematic review protocol**
5

6 3
7 4 Simon C Mendelsohn¹, Humphrey Mulenga¹, Stanley Kimbung Mbandi¹, Fatoumatta Darboe¹,
8 5 Mary Shelton², Thomas J Scriba^{1*}, Mark Hatherill^{1*}
9 6

10
11 6
12 7 *TJS and MH contributed equally to this work.
13
14 8

15 9 **Author affiliations:**

16
17 10 ¹South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular
18 11 Medicine, Division of Immunology, Department of Pathology, University of Cape Town, Cape
19 12 Town, South Africa.

20 12
21 13 ²Bongani Mayosi Health Sciences Library, University of Cape Town, Cape Town, South Africa.
22 13
23 14

24
25 15 **Corresponding author:** Mark Hatherill

26 16 **Email:** Mark.Hatherill@uct.ac.za **Telephone:** +27 (0) 21 406 6080

27 16
28 17 **Postal address:** South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and
29 18 Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town,
30 19 Anzio Road, Observatory, 7935, Cape Town, South Africa.
31 19
32 20

33 20
34 21 **Keywords:** Human, host, blood, diagnostic, prognostic, predictive, transcriptomic, mRNA, gene
35 22 expression, biomarker, signature, tuberculosis, *Mycobacterium*, TB, HIV
36 22
37 23

38 23
39 24 **Word count:** 3,174
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

25 26 **ABSTRACT**

27 **Introduction**

28 Current tuberculosis triage and predictive tools offer poor accuracy and are ineffective for detecting
29 asymptomatic disease in people living with HIV (PLHIV). Host tuberculosis transcriptomic
30 biomarkers hold promise for diagnosing prevalent and predicting progression to incident
31 tuberculosis, and guiding further investigation, preventive therapy, and follow-up. We aim to conduct
32 a systematic review of performance of transcriptomic signatures of tuberculosis in PLHIV.
33

34 **Methods and analysis**

35 We will search *MEDLINE (PubMed)*, *WOS Core Collection*, *Biological Abstracts*, and *SciELO*
36 *Citation Index (Web of Science)*, *Africa-Wide Information and General Science Abstracts*
37 *(EBSCOhost)*, *Scopus*, and *Cochrane Central Register of Controlled Trials* databases for articles
38 published in English between 1990–2020. Case-control, cross-sectional, cohort and randomised-
39 controlled studies evaluating performance of diagnostic and prognostic host-response transcriptomic
40 signatures in PLHIV of all ages and settings will be included. Eligible studies will include PLHIV in
41 signature test or validation cohorts, and use microbiological, clinical, or composite reference
42 standards for pulmonary or extra-pulmonary tuberculosis diagnosis. Study quality will be evaluated
43 using the “Quality Assessment of Diagnostic Accuracy Studies-2” tool and cumulative review
44 evidence assessed using the “Grading of Recommendations Assessment, Development and
45 Evaluation” approach. Study selection, quality appraisal, and data extraction will be performed
46 independently by two reviewers. Study, cohort, and signature characteristics of included studies will
47 be tabulated, and a narrative synthesis of findings presented. Primary outcomes of interest,
48 biomarker sensitivity and specificity with estimate precision, will be summarised in forest plots.
49 Expected heterogeneity in signature characteristics, study settings, and study designs precludes
50 meta-analysis and pooling of results. Review reporting will follow the Preferred Reporting Items for
51 Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy Studies guidelines.
52

53 **Ethics and dissemination**

54 Formal ethics approval is not required as primary human participant data will not be collected.
55 Results will be disseminated through peer-reviewed publication and conference presentation.
56

57 **PROSPERO registration:** CRD42021224155
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

- This systematic review will be the first to synthesise the published literature on host-response blood transcriptomic biomarkers for diagnosing prevalent and predicting progression to incident tuberculosis disease in people living with HIV.
- Data reporting will adhere to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) guidelines.
- Strengths of this protocol include a clear research question with explicit and reproducible methodology, comprehensive eligibility criteria with a stringent microbiological reference standard as well as clinical and composite reference standards for tuberculosis disease, inclusion of participants of all ages and recruitment settings, a rigorous and inclusive search strategy of multiple databases, and structured evaluation of study bias and evidence quality using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) assessment tool and Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
- Inclusion will be restricted to published studies in English which may introduce publication and language bias.
- Anticipated limitations of this review include heterogenous signature, study, and cohort designs, precluding meta-analysis.

INTRODUCTION

In 2019 44% of the estimated 815,000 global incident tuberculosis cases amongst people living with HIV (PLHIV) went unreported or undiagnosed, with an estimated case fatality rate of 26% amongst all PLHIV.¹ We currently rely on symptom screening, which performs poorly as a triage test in PLHIV, to find these missing cases.² A test which could detect *Mycobacterium tuberculosis* (*Mtb*) infected individuals at highest risk of progression to disease, so-called incipient tuberculosis, or asymptomatic, minimal, or sub-clinical tuberculosis disease prior to symptom onset, facilitating earlier treatment and *Mtb* clearance, may reduce morbidity and mortality in PLHIV, and help to interrupt transmission. Tuberculin skin testing (TST) and the interferon gamma release assay (IGRA), which reflect a memory T-cell response following *Mtb* sensitisation, are unable to distinguish current versus cleared *Mtb* infection and are thus not sufficiently specific for predicting progression to tuberculosis disease.^{3,4} In tuberculosis-endemic settings, very high rates of *Mtb* exposure and consequent TST or IGRA positivity limit the utility of these tests to guide administration of tuberculosis preventive therapy (TPT). IGRA also has lower sensitivity and produces more indeterminate results amongst PLHIV than amongst those without HIV.⁵ There is therefore a need for more specific, rapid, non-sputum tuberculosis triage and prognostic tools to direct further diagnostic testing and TPT in PLHIV.

Host-response blood transcriptomic biomarkers show potential for diagnosing^{6,7} prevalent tuberculosis and predicting⁸ progression from asymptomatic quiescent or incipient infection to active disease. A recent systematic review⁹ found 20 studies evaluating 25 predominantly interferon-stimulated gene (ISG) transcriptomic signatures of tuberculosis in adults without HIV; 17 signatures met at least one of the World Health Organization (WHO) Target Product Profile (TPP) minimum performance criterion for a tuberculosis triage test (sensitivity 90%; specificity 70%)¹⁰ and one signature¹¹ predicted progression to tuberculosis disease through 6 months with performance meeting the minimum WHO TPP criteria for a test predicting progression to active disease (sensitivity and specificity 75%)¹². Although these results bode well for translation to a point-of-care transcriptomic triage test for people without HIV, there is evidence that HIV infection may affect signature score through induction of ISGs¹³. An unsuppressed HIV viral load may thus erode diagnostic accuracy of ISG-dominant transcriptomic biomarkers. There are currently no systematic reviews evaluating diagnostic and prognostic performance of host-response blood transcriptomic tuberculosis biomarkers in PLHIV. Biomarkers selected for further development as point-of-care tests and field implementation studies in high-tuberculosis-risk groups should ideally perform well in people without HIV and in PLHIV, before and during antiretroviral therapy (ART).

We aim to systematically review the published literature on host-response blood transcriptomic biomarkers for diagnosing prevalent and predicting progression to incident tuberculosis disease in PLHIV. Our objectives are to provide an evidence synthesis of existing transcriptomic host-response

1
2 114 biomarkers of tuberculosis disease evaluated in PLHIV; to appraise the quality of evidence, describe
3 115 study design and biomarker characteristics, and compare the diagnostic and prognostic performance
4 116 of the biomarkers with the WHO TPP criteria.
5 117

8 118 **RESEARCH QUESTION**

9
10 119 How do host blood transcriptomic signatures of tuberculosis perform in diagnosing prevalent and
11 120 predicting progression to incident tuberculosis disease in PLHIV compared to the WHO TPP criteria?
12 121

13 121
14 122 **Population:** PLHIV of all ages and from all settings

15 122
16 123 **Index test:** Blood transcriptomic biomarkers

17 124 **Reference standard:** Microbiologically-confirmed tuberculosis (primary endpoint) or non-
18 124 microbiologically-confirmed, presumptive clinical tuberculosis (secondary endpoint)
19 125

20 126 **Comparator:** WHO TPP criteria

21 126
22 127 **Outcome:** Diagnosis of prevalent and prediction of progression to incident tuberculosis disease
23 128

24 128 25 129 **METHODS AND ANALYSIS**

26 129
27 130 This protocol was developed in line with the Preferred Reporting Items for Systematic review and
28 130 Meta-Analysis Protocols (PRISMA-P)^{14,15} guidelines (Supplementary File). The systematic review
29 131 will adhere to the Preferred Reporting Items for Systematic reviews and Meta-Analysis of Diagnostic
30 132 Test Accuracy Studies (PRISMA-DTA)¹⁶ recommendations. Significant amendments made to the
31 132 protocol will be documented and published alongside the results of the systematic review. This
32 133 systematic review protocol was registered with the International Prospective Register of Systematic
33 134 Reviews (PROSPERO) on 02 January 2021 with registration number CRD42021224155.
34 134
35 135
36 136
37 136
38 137

39 137 40 138 **Definitions and study eligibility criteria**

41 139 *Study design*

42 139
43 140 Study eligibility criteria are summarised in **Table 1**. We will consider cross-sectional and case-control
44 141 studies, prospective and retrospective cohort studies, and randomised control trials of human host
45 141 diagnostic or prognostic transcriptomic signatures of tuberculosis that report test or validation cohort
46 142 performance data. Studies that only report signature discovery cohort performance, or treatment
47 143 response and failure monitoring cohorts, will not be considered.
48 143
49 144
50 144

51 145 52 146 *Study participants and setting*

53 146
54 147 We will consider study participants living with HIV of all ages, ethnicities, and settings, and include
55 148 ART-naïve and ART-experienced individuals. Eligible studies must include participants living with
56 148 HIV in either the signature test or validation cohorts. If the study encompasses both PLHIV and HIV-
57 149 uninfected individuals, the study will only be included if the data are stratified by HIV subgroups.
58 150
59 150
60 151

152 *Index test*

153 We define diagnostic blood transcriptomic signatures of tuberculosis as host whole-blood or
154 peripheral blood mononuclear cell (PBMC) biomarkers consisting of one or more host transcripts
155 which are able to diagnose or predict progression to tuberculosis disease and have been validated
156 in external cohorts. Studies which only evaluate non-host (mycobacterial) transcriptional profiles as
157 diagnostic biomarkers will be excluded.

159 *Tuberculosis endpoints*

160 The primary tuberculosis disease endpoint is defined by a positive microbiological test from sputum
161 or other bodily fluids, such as solid and liquid mycobacterial culture, Xpert MTB/RIF assay, or smear
162 microscopy for acid-fast bacilli (auramine and Ziehl-Neelsen stains). Microbiologically-confirmed
163 extra-pulmonary tuberculosis disease (such as disseminated tuberculosis and tuberculosis
164 meningitis) will also be included. The secondary tuberculosis disease endpoint is defined by non-
165 microbiologically-confirmed, presumptive clinical tuberculosis diagnoses through techniques such
166 as chest radiography, ultrasonography, fluid aspirate (e.g. lymph node and cerebrospinal fluid
167 aspirates) chemistry, symptomatology, and composite non-microbiological endpoints. Latent
168 tuberculosis infection is defined by a positive tuberculin skin test (TST) or interferon-gamma release
169 assay (IGRA).

170
171 Eligible studies will use the primary microbiological tuberculosis reference standard endpoint or
172 secondary presumptive clinical diagnosis endpoint for tuberculosis disease cases. Studies which do
173 not separate clinically- from microbiologically-diagnosed cases will be excluded. Studies which use
174 smear microscopy as a reference standard will be reported separately due to reduced diagnostic
175 certainty. Eligible studies must include healthy individuals, individuals with latent *Mtb* infection, or
176 individuals with other diseases as a control group. Tuberculosis disease diagnosed within one month
177 of conducting the index test is presumed to be prevalent disease (diagnostic studies); incident
178 tuberculosis is defined as tuberculosis disease diagnosed more than one month following study
179 enrolment or measurement of index test. Prognostic studies are defined as prospective studies in
180 which participants are followed up for progression to incident tuberculosis disease with prospective
181 or retrospective measurement of a transcriptomic biomarker from blood RNA samples collected at
182 enrolment.

184 *Outcome measures*

185 Outcome measures of interest will include reported host tuberculosis transcriptomic signature
186 sensitivity and specificity in test or validation cohorts, or reported data which enable the
187 reconstruction of a two-by-two table for test accuracy calculation for PLHIV. Studies which do not
188 report any measures of signature performance, do not clearly state the case definition of tuberculosis
189 disease, do not report primary data, lack explicit description of methodology, or do not separately

report signature performance in PLHIV, will be excluded. If data supplied in the papers are not sufficient to reconstruct two-by-two tables, we will contact the corresponding authors to request additional data. Corresponding authors will be given up to four weeks to respond to email requests.

Table 1: Study eligibility criteria

Study inclusion criteria	
1.	Study design: Cross-sectional, case-control, prospective/retrospective cohort, or randomised control
2.	Study reports test and/or validation cohort diagnostic or prognostic performance data
3.	Study participants include people living with HIV in test and/or validation cohort. Studies including human participants of all ages, geographic locations, and settings will be considered.
4.	Index test: Study evaluates whole-blood or peripheral blood mononuclear cell (PBMC) diagnostic transcriptomic signatures of tuberculosis consisting of one or more host transcripts
5.	Control group: Includes healthy individuals, individuals with <i>Mtb</i> infection, and/or individuals with other diseases.
6.	Tuberculosis endpoint: Studies will provide clearly defined microbiological tuberculosis reference standard or presumptive clinical diagnosis definitions (<i>see Tuberculosis endpoints</i>)
7.	Outcome measures: Host tuberculosis transcriptomic signature sensitivity and specificity in test or validation cohorts, or reported data which enable the reconstruction of a two-by-two table for test accuracy calculation
Study exclusion criteria	
1.	Study design: Statistical or mathematical modelling articles, cost-effectiveness studies, opinion pieces, narrative reviews, case studies, case series, and letters to editors which do not include original data will not be considered.
2.	Study only reports signature discovery cohort performance, or treatment response, or failure monitoring cohorts
3.	Study participants do not include PLHIV, or it is not possible to stratify results by HIV status
4.	Index test: Study evaluates non-host (mycobacterial) transcriptional profiles only
5.	Control group: Studies which do not report a definition of the control group
6.	Tuberculosis endpoint: Studies which do not clearly state the case definition of tuberculosis disease, or do not separate clinically- from microbiologically-diagnosed cases
7.	Outcome measures: Studies which do not report any measures of signature performance, or do not separately report signature performance in PLHIV
8.	Article not available in English
9.	Full-text article not available
10.	Study published before 1 January 1990 or after 31 December 2020
11.	Studies conducted in animals

Search strategy

We will systematically search for published full-text articles using Medical Subject Headings (MeSH) and keyword search terms as outlined for our PubMed (*MEDLINE*) search in **Table 2**. Our systematic literature search will be adapted to *WOS Core Collection*, *Biological Abstracts*, and *SciELO Citation Index (via Web of Science)*, *Africa-Wide Information* and *General Science Abstracts (via EBSCOhost)*, *Scopus*, and *Cochrane Central Register of Controlled Trials* databases. We will review reference lists of eligible articles and perform forward citation tracking using a citation index (such as *Scopus* or *Science Citation Index via Web of Science*) to identify further articles and reports missed by the electronic database search.¹⁷ Only full-text articles will be considered. Statistical or mathematical modelling articles, cost-effectiveness studies, opinion pieces, narrative reviews, case studies, case series, and letters to editors which do not include original data will not be considered. We will consider articles published in English between 1 January 1990 and 31 December 2020.

Table 2: PubMed Search strategy, modified as needed for other electronic databases

Diagnostic search terms:		
#1	MeSH terms:	Diagnosis [MeSH] Diagnosis [subheading]
#2	Text word:	diagnose OR diagnostic OR diagnosis OR detect OR detection OR predict OR prediction OR predictive OR prognose OR prognostic OR prognosis OR receiver operating characteristic OR receiver operator characteristic OR ROC OR risk OR screening OR sensitivity OR specificity OR area under the curve OR AUC OR accuracy
#3	#1 OR #2	
Transcriptomic:		
#4	MeSH terms:	RNA, Messenger [MeSH]
#5	Text word:	gene OR genes OR mRNA OR messenger ribonucleic acid OR messenger RNA OR transcription OR transcriptome OR transcriptional OR transcriptomic
#6	#4 OR #5	
Biomarker:		
#7	MeSH terms:	Biomarkers/blood [MeSH]
#8	Text word:	assay OR assays OR biomarker OR biomarkers OR bio-signature OR bio-signatures OR expression OR marker OR markers OR profile OR profiling OR profiles OR signature OR signatures OR surrogate endpoint OR test OR tests OR tool OR tools
#9	#7 OR #8	
Tuberculosis:		
#10	MeSH terms:	Tuberculosis [MeSH] Mycobacterium, Tuberculosis [MeSH]
#11	Text word:	tuberculosis OR TB OR MTB
#12	#10 OR #11	
HIV:		
#13	MeSH terms:	HIV[MeSH] Acquired Immunodeficiency Syndrome [MeSH]
#14	Text word:	HIV OR Human Immunodeficiency Virus OR AIDS virus OR Acquired Immune Deficiency Syndrome Virus
#15	#13 OR #14	
#16	#3 AND #6 AND #9 AND #12 AND #15	
#17	Filter 1990-2020	
#18	Filter to English only	

Data management

EndNote bibliographic software will be used to manage, and screen references and full-text articles as previously described¹⁸. Two reviewers will independently conduct the literature search and screen the search outputs for potential inclusion. After removal of duplicates, the selection process will include an initial screening of article titles and abstracts (include, exclude, or unsure), followed by full text review for eligibility. Only studies meeting the eligibility criteria will be included in the systematic review. The two reviewers will compare their results and resolve any disagreements or uncertainties by discussion. If consensus cannot be reached, the discrepancies will be referred to a third a reviewer for adjudication. Study selection will be summarised in a PRISMA flow diagram.

1
2 220
3
4 221
5 222
6
7 223
8 224
9
10 225
11 226
12
13 227
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48 228
49 229
50
51 230
52 231
53 232
54
55 233
56
57 234
58 235
59
60 236
237

Data extraction

Data elements (**Table 3**) of included studies will be independently extracted and coded by the two reviewers using an electronic data collection form and results will be collated. The data extraction form will be piloted on the first five studies selected for inclusion to assess agreement between the two reviewers and need for amendments to the data collection form.

Table 3: Summary of data extraction

Study identification	Study first author; article title; journal title; publication year; study type (discovery and/or validation; diagnostic and/or prognostic);
Cohort identification and methodology	Cohort first author; journal title; publication year; GEO and/or ArrayExpress database; country or geographic region of the study; cohort type (discovery, test, or validation); study design (cross-sectional, case control, prospective cohort, randomised control trial, or other); study setting; age groups of participants (child, adolescent, adult, or mixed); sample size; sampling method and participant selection (consecutive, convenience, random, other); sample representative of target population (were participants with suspected but unconfirmed tuberculosis excluded introducing spectrum bias); control group definition (LTBI, healthy control, and/or other disease); microbiological reference standard(s) used to diagnose tuberculosis disease; clinical and/or composite non-microbiological methods of tuberculosis diagnosis; method of LTBI diagnosis (TST >5mm, TST >10mm, IGRA: T-Spot.TB or QuantiFERON); duration of follow-up for prediction of progression to incident tuberculosis; signature measurement method (RNA sequencing, microarray, PCR, or other) and sample type (whole blood or PBMC); flow and timing of index and reference test measurement; study blinding
Signature characteristics	Signature discovery author; publication year; country or geographic region of discovery cohort; study design; signature discovery method (RNA sequencing, microarray, PCR, or other) and sample type (whole blood or PBMC); transcripts included in the signature; signature model; intended use of signature
Outcome data	True and false positives; true and false negatives; sensitivity; specificity; area under the curve; signature positivity rate (prevalence) in study population; signature cut-off/threshold applied (if reported); 95% confidence intervals for all estimates

GEO, gene expression omnibus. LTBI, latent tuberculosis infection. TST, tuberculin skin test. IGRA, interferon-gamma release assay. RNA, ribonucleic acid. PCR, polymerase chain reaction. PBMC, peripheral blood mononuclear cells.

A study may evaluate multiple signatures using several validation cohorts. Studies and cohorts will be designated by the first author name and year of publication (e.g. Author2019a) and signatures by first author and number of transcripts (e.g. Author11).

Quality appraisal

The methodological quality of included studies will be assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) assessment tool¹⁹, a widely used tool for classification of the quality of the evidence from diagnostic accuracy studies. Risk of bias and applicability concerns for individual study patient selection, index test, reference standard, and study flow and timing will be reported as low risk, high risk, or unclear risk.

Two independent reviewers will assess the methodological quality of eligible trials and score the selected studies. Disagreements will be resolved through discussion and/or a third reviewer. The risk of bias for each outcome across individual studies will be summarised in a risk of bias table. A review-level narrative summary of the risk of bias will also be provided.

We will assess the cumulative quality of evidence synthesised by the systematic review using the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) approach²⁰ with classification based on study design and limitations, indirectness, inconsistency, imprecision, and publication bias.²¹

Data analysis and reporting

Narrative synthesis of the findings from the eligible studies, including study design and signature characteristics, discovery and validation population characteristics, and performance of each signature, stratified by diagnostic (prevalent tuberculosis) and prognostic (incident tuberculosis) tests, study design, site of disease (pulmonary or extra-pulmonary), microbiological or composite clinical reference standards, and control group (healthy, latent-*Mtb* infected, or other disease) will be provided. We anticipate considerable clinical and methodological heterogeneity between studies, with each study evaluating different transcriptomic signatures for the diagnosis of tuberculosis disease. In addition, signature score cut-off values will not be standardised for calculating signature sensitivity and specificity. As such, we do not plan to perform a meta-analysis. If sufficient data is available, subgroup analysis by CD4 cell count, HIV plasma viral load, TPT and ART status may be undertaken. Signature sensitivity and specificity will be summarised using forest plots.

PATIENT AND PUBLIC INVOLVEMENT

As this research will be based on previously published data, there will be no patient and public involvement in the design, interpretation or dissemination of the findings.

ETHICS AND DISSEMINATION

This systematic review protocol does not require formal ethics approval as primary human participant data will not be collected. The results will be disseminated through a peer-reviewed publication and conference presentation.

1
2 276
3
4 277
5 278
6
7 279
8 280
9
10 281
11 282
12
13 283
14
15 284
16 285
17
18 286
19 287
20
21 288
22 289
23
24 290
25
26 291
27 292
28
29 293
30 294
31
32 295
33
34 296
35 297
36
37 298
38 299
39
40 300
41 301
42
43 302
44
45 303
46 304
47
48 305
49 306
50
51 307
52 308
53
54 309
55
56 310
57 311
58
59 312
60 313

DISCUSSION

Transcriptomic biomarkers hold promise as markers of incipient, asymptomatic, minimal, or sub-clinical tuberculosis for targeted screening of high risk populations, guiding targeted TPT and intensified follow-up.²² There is also need for non-sputum-based triage tests for detection of sub-clinical and clinical tuberculosis, to trigger further intensified investigation and therapeutic intervention.²³

While several studies have recently systematically evaluated transcriptomic biomarker performance for incipient and prevalent tuberculosis,^{7-9,24,25} none have specifically focussed on PLHIV. As highlighted in the introduction, PLHIV are over-represented in global tuberculosis incidence and have a particularly high case-fatality rate. PLHIV are also less likely to expectorate sputum while paucibacillary tuberculosis is more common, factors that make diagnosis even more challenging in PLHIV.²⁶ As such, it is important that non-sputum tuberculosis biomarkers selected for further development and commercialisation are efficacious in this high-risk population. This systematic review will be the first to provide synthesis of transcriptomic signature performance in diagnosing prevalent and predicting progression to incident tuberculosis in PLHIV.

A rigorous protocol acts as a roadmap to the reviewers; by pre-specifying and registering a detailed systematic review protocol, we aim to reduce bias in selection of studies and reporting of results, reducing arbitrary decision-making in data extraction, quality assessment, and analysis. This protocol will allow journal editors, peer reviewers, and readers to critically gauge the review completeness and transparency, identify deviations from planned methods, and identify biased interpretation of review results and conclusions, holding accountability to the reviewers.¹⁴ Specific strengths of this systematic review protocol include a clear research question, explicit and reproducible methodology, comprehensive eligibility criteria with a stringent microbiological reference standard, as well as clinical and composite endpoints for tuberculosis disease, inclusion of participants of all ages and recruitment settings, a rigorous and inclusive search strategy of multiple databases, and structured evaluation of study bias and evidence quality.

Potential limitations of this study include the heterogeneity of measures and outcomes reported by biomarker discovery and validation studies, with few studies applying a-priori biomarker thresholds across cohorts or one that is relevant to the WHO TPP criteria. We anticipate scant reporting of signature performance stratified by ART and TPT status, CD4 cell count, and HIV viral load, limiting sub-group analysis. We are also aware that much of the tuberculosis biomarker literature in PLHIV emanates from Sub-Saharan Africa, potentially limiting generalisability of findings. We expect significant heterogeneity in signature, study, and cohort designs, precluding meta-analysis. Inclusion of studies published in English only may introduce publication bias. Diagnosing tuberculosis in

1
2 314 PLHIV can be particularly challenging due to more common paucibacillary disease and difficulties in
3 315 expectorating sputum in advanced HIV; we thus chose to include clinical and composite diagnostic
4 316 endpoints which are still used in many settings to presumptively initiate tuberculosis treatment.
5 317 However, this may lead to overdiagnosis of tuberculosis and under-estimation of transcriptomic
6 318 biomarker performance. Clinically diagnosed symptomatic disease without microbiological
7 319 confirmation remains an enigma which merits further attention beyond the scope of this review.
8
9

10 320
11 321 This review will inform further optimisation and development of transcriptomic signatures as they
12 322 progress through the clinical implementation pipeline. Transcriptomic signatures discovered and
13 323 validated in high quality studies with well-designed cohorts and meeting or approaching the WHO
14 324 TPP criteria may be considered for advancement for further prospective validation in real-world
15 325 health-care settings and development as point-of-care tests for PLHIV who are at elevated risk of
16 326 tuberculosis and its sequelae. The review may also inform whether current WHO TPP benchmarks
17 327 can realistically be attained in PLHIV, and whether they need to be revisited.
18
19
20
21
22
23

24 328 25 329 **AUTHORS' CONTRIBUTIONS**

26 330 SCM and MH conceived the idea and planned the study protocol. SCM, MS, and MH undertook a
27 331 scoping search and designed the search strategy. SCM wrote the protocol under supervision from
28 332 MH and TJS. SCM, HM, SKM, FD, MS, TJS, and MH have contributed to, reviewed, and approved
29 333 the final protocol, and will participate in the interpretation of the results.
30
31
32
33
34

35 335 **FUNDING STATEMENT**

36 336 This research received no specific grant from any funding agency in the public, commercial, or not-
37 337 for-profit sectors. SCM is a recipient of PhD funding from the Fogarty International Center of the
38 338 National Institutes of Health (NIH) under Award Number D43 TW010559, the Harry Crossley Clinical
39 339 Research Fellowship, the South African Medical Research Council (SAMRC) through its Division of
40 340 Research Capacity Development under the SAMRC Clinician Researcher Programme, and the
41 341 South African Medical Association (SAMA). The content is solely the responsibility of the authors
42 342 and does not necessarily represent the official views of the NIH, Harry Crossley Foundation,
43 343 SAMRC, or SAMA.
44
45
46
47
48
49
50

51 345 **COMPETING INTERESTS STATEMENT**

52 346 TJS is a co-inventor of two patents of host-blood transcriptomic signatures of tuberculosis risk.
53
54
55
56
57
58
59
60

1
2 347 **REFERENCES**

- 3 348 1. WHO. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
4 349 https://www.who.int/tb/publications/global_report/en/ (accessed October 15, 2020).
- 5 350 2. Hamada Y, Lujan J, Schenkel K, Ford N, Getahun H. Sensitivity and specificity of WHO's
6 351 recommended four-symptom screening rule for tuberculosis in people living with HIV: a
7 352 systematic review and meta-analysis. *Lancet HIV*. 2018;5(9):e515-e23. doi: 10.1016/S2352-
8 353 3018(18)30137-1.
- 9 354 3. Barry CE, 3rd, Boshoff HI, Dartois V, Dick T, Ehrh S, Flynn J, et al. The spectrum of latent
10 355 tuberculosis: rethinking the biology and intervention strategies. *Nature Reviews Microbiology*.
11 356 2009;7(12):845-55. doi: 10.1038/nrmicro2236.
- 12 357 4. Mahomed H, Hawkridge T, Verver S, Abrahams D, Geiter L, Hatherill M, et al. The tuberculin
13 358 skin test versus QuantiFERON TB Gold(R) in predicting tuberculosis disease in an
14 359 adolescent cohort study in South Africa. *PLoS ONE*. 2011;6(3):e17984. doi:
15 360 10.1371/journal.pone.0017984.
- 16 361 5. Metcalfe JZ, Everett CK, Steingart KR, Cattamanchi A, Huang L, Hopewell PC, et al.
17 362 Interferon-gamma release assays for active pulmonary tuberculosis diagnosis in adults in
18 363 low- and middle-income countries: systematic review and meta-analysis. *Journal of*
19 364 *Infectious Diseases*. 2011;204 Suppl 4:S1120-9. doi: 10.1093/infdis/jir410.
- 20 365 6. Warsinske H, Vashisht R, Khatri P. Host-response-based gene signatures for tuberculosis
21 366 diagnosis: A systematic comparison of 16 signatures. *PLoS Medicine*. 2019;16(4):e1002786.
22 367 doi: 10.1371/journal.pmed.1002786.
- 23 368 7. Turner CT, Gupta RK, Tsaliki E, Roe JK, Mondal P, Nyawo GR, et al. Blood transcriptional
24 369 biomarkers for active pulmonary tuberculosis in a high-burden setting: a prospective,
25 370 observational, diagnostic accuracy study. *Lancet Respir Med*. 2020;8(4):407-19. doi:
26 371 10.1016/S2213-2600(19)30469-2.
- 27 372 8. Gupta RK, Turner CT, Venturini C, Esmail H, Rangaka MX, Copas A, et al. Concise whole
28 373 blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-
29 374 level pooled meta-analysis. *Lancet Respir Med*. 2020;8(4):395-406. doi: 10.1016/S2213-
30 375 2600(19)30282-6.
- 31 376 9. Mulenga H, Zauchenberger CZ, Bunyasi EW, Mbandi SK, Mendelsohn SC, Kagina B, et al.
32 377 Performance of diagnostic and predictive host blood transcriptomic signatures for
33 378 Tuberculosis disease: A systematic review and meta-analysis. *PLoS ONE*.
34 379 2020;15(8):e0237574. doi: 10.1371/journal.pone.0237574.
- 35 380 10. WHO. High-priority target product profiles for new tuberculosis diagnostics: report of a
36 381 consensus meeting. Geneva: World Health Organization, 2014.
37 382 www.who.int/tb/publications/tpp_report/en/ (accessed May 22, 2020).
- 38 383 11. Warsinske HC, Rao AM, Moreira FMF, Santos PCP, Liu AB, Scott M, et al. Assessment of
39 384 Validity of a Blood-Based 3-Gene Signature Score for Progression and Diagnosis of
40 385 Tuberculosis, Disease Severity, and Treatment Response. *JAMA Netw Open*.
41 386 2018;1(6):e183779. doi: 10.1001/jamanetworkopen.2018.3779.
- 42 387 12. WHO. Consensus Meeting Report: Development of a Target Product Profile (TPP) and a
43 388 framework for evaluation for a test for predicting progression from tuberculosis infection to
44 389 active disease. Geneva: World Health Organization, 2017.
45 390 <http://apps.who.int/iris/handle/10665/259176> (accessed May 22, 2020).
- 46 391 13. Darboe F, Mbandi SK, Naidoo K, Yende-Zuma N, Lewis L, Thompson EG, et al. Detection
47 392 of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic
48 393 Risk Signature in HIV-Infected Persons on Antiretroviral Therapy. *Front Microbiol*.
49 394 2019;10:1441. doi: 10.3389/fmicb.2019.01441.
- 50 395 14. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting
51 396 items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst*
52 397 *Rev*. 2015;4:1. doi: 10.1186/2046-4053-4-1.
- 53 398 15. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting
54 399 items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and
55 400 explanation. *BMJ*. 2015;350:g7647. doi: 10.1136/bmj.g7647.
- 56 401 16. McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, the P-DTAG, et al. Preferred
57 402 Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy

- 1
2 403 Studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388-96. doi:
3 404 10.1001/jama.2017.19163.
4 405 17. Greenhalgh T, Peacock R. Effectiveness and efficiency of search methods in systematic
5 406 reviews of complex evidence: audit of primary sources. BMJ. 2005;331(7524):1064-5. doi:
6 407 10.1136/bmj.38636.593461.68.
7 408 18. Peters MD. Managing and Coding References for Systematic Reviews and Scoping Reviews
8 409 in EndNote. Medical Reference Services Quarterly. 2017;36(1):19-31. doi:
9 410 10.1080/02763869.2017.1259891.
10 411 19. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2:
11 412 a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal
12 413 Medicine. 2011;155(8):529-36. doi: 10.7326/0003-4819-155-8-201110180-00009.
13 414 20. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an
14 415 emerging consensus on rating quality of evidence and strength of recommendations. BMJ.
15 416 2008;336(7650):924-6. doi: 10.1136/bmj.39489.470347.AD.
16 417 21. Schünemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading
17 418 quality of evidence and strength of recommendations for diagnostic tests and strategies.
18 419 BMJ. 2008;336(7653):1106-10. doi: 10.1136/bmj.39500.677199.AE.
19 420 22. Scriba TJ, Mendelsohn SC. Headway made towards biosignatures for incipient tuberculosis.
20 421 Lancet Respir Med. 2020;8(4):328-30. doi: 10.1016/s2213-2600(19)30355-8.
21 422 23. Mendelsohn SC, Mbandi SK, Hatherill M, Scriba TJ. Blood transcriptional signatures for
22 423 tuberculosis testing. Lancet Respir Med. 2020;8(4):330-1. doi: 10.1016/S2213-
23 424 2600(20)30045-X.
24 425 24. Togun TO, MacLean E, Kampmann B, Pai M. Biomarkers for diagnosis of childhood
25 426 tuberculosis: A systematic review. PLoS ONE. 2018;13(9):e0204029. doi:
26 427 10.1371/journal.pone.0204029.
27 428 25. MacLean E, Broger T, Yerlikaya S, Fernandez-Carballo BL, Pai M, Denkinge CM. A
28 429 systematic review of biomarkers to detect active tuberculosis. Nat Microbiol. 2019;4(5):748-
29 430 58. doi: 10.1038/s41564-019-0380-2.
30 431 26. MacLean E, Saravu K, Pai M. Diagnosing active tuberculosis in people living with HIV: an
31 432 ongoing challenge. Current Opinion in HIV and AIDS. 2019;14(1):46-54. doi:
32 433 10.1097/COH.0000000000000512.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Host blood transcriptomic biomarkers of tuberculosis disease in people living with HIV: a systematic review protocol

Supplementary File: PRISMA-P 2015 Checklist

This checklist has been adapted for use with protocol submissions to *Systematic Reviews* from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews* 2015 4:1

Section/topic	#	Checklist item	Information reported		Location
			Yes	No	
ADMINISTRATIVE INFORMATION					
Title					
Identification	1a	Identify the report as a protocol of a systematic review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Line 2, Page 1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	<input type="checkbox"/>	<input type="checkbox"/>	N/A
Registration	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Line 57, Page 2; lines 135-136 page 5
Authors					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Page 1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 329-333, Page 12
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 133-134, Page 5
Support					
Sources	5a	Indicate sources of financial or other support for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 335-343, Page 12
Sponsor	5b	Provide name for the review funder and/or sponsor	<input type="checkbox"/>	<input type="checkbox"/>	N/A
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	<input type="checkbox"/>	<input type="checkbox"/>	N/A
INTRODUCTION					
Rationale	6	Describe the rationale for the review in the context of what is already known	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 94-109, Page 4
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 118-127, Page 5

Host blood transcriptomic biomarkers of tuberculosis disease in people living with HIV: a systematic review protocol

Supplementary File: PRISMA-P 2015 Checklist

Section/topic	#	Checklist item	Information reported		Location
			Yes	No	
METHODS					
Eligibility criteria	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Table 1; Lines 138-208, Pages 5-7
Information sources	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 197-207, Page 7
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Table 2, Page 8
STUDY RECORDS					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 211-219, Pages 8
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 213-219, Pages 8
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 221-234, Page 9
Data items	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Table 3, Page 9
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 184-193, Pages 6-7; Table 3, Page 9
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 238-248, Page 10
DATA					

Host blood transcriptomic biomarkers of tuberculosis disease in people living with HIV: a systematic review protocol

Supplementary File: PRISMA-P 2015 Checklist

Section/topic	#	Checklist item	Information reported		Location
			Yes	No	
Synthesis	15a	Describe criteria under which study data will be quantitatively synthesized	<input checked="" type="checkbox"/>	<input type="checkbox"/>	N/A: See lines 261-264, Page 10
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I^2 , Kendall's tau)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 263-266, Page 10
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 255-266, Page 10
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 306-319, Pages 11-12
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lines 250-253, Page 10